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Abstract
Background: Although many genetic variants have been associated with multiple sclerosis (MS) risk, they do not
explain all the disease risk and there remains uncertainty as to how these variants contribute to disease. DNA
methylation is an epigenetic mechanism that can influence gene expression and has the potential to mediate the
effects of environmental factors on MS. In a previous study, we found a differentially methylation region (DMR) at
MHC HLA-DRB1 that was associated within relapsing-remitting MS (RRMS) patients in CD4+ T cells. This study aimed
to confirm this earlier finding in an independent RRMS cohort of treatment-naïve female patients.
Methods: Total genomic DNA was extracted from CD4+ T cells of 28 female RRMS and 22 age-matched healthy
controls subjects. DNA was bisulfite-converted and hybridised to Illumina 450K arrays. Beta values for all CpGs were
analysed using the DMPFinder function in the MINFI program, and a follow-up prioritisation process was applied to
identify the most robust MS-associated DMRs.
Results: This study confirmed our previous findings of a hypomethylated DMR at HLA-DRB1 and a hypermethylated
DMR at HLA-DRB5 in this RRMS patient cohort. In addition, we identified a large independent DMR at MHC, whereby
11 CpGs in RNF39 were hypermethylated in MS cases compared to controls (max. Δbeta = 0.19, P = 2.1 × 10−4).
We did not find evidence that SNP genotype was influencing the DMR in this cohort. A smaller MHC DMR was also
identified at HCG4B, and two non-MHC DMRs at PM20D1 on chr1 and ERICH1 on chr8 were also identified.
Conclusions: The findings from this study confirm our previous results of a DMR at HLA-DRB1 and also suggest
hypermethylation in an independent MHC locus, RNF39, is associated with MS. Taken together, our results highlight
the importance of epigenetic factors at the MHC locus in MS independent of treatment, age and sex. Prospective
studies are now required to discern whether methylation at MHC is involved in influencing risk of disease onset or
whether the disease itself has altered the methylation profile.
Background
Multiple sclerosis (MS) is an autoimmune disease char-
acterised by lymphocyte-mediated inflammation caus-
ing demyelination and axonal degeneration. The
underlying pathogenesis of MS remains unclear, but the
risk of developing MS is influenced by a combination
of genetic predisposition and environmental exposures.
Several large genome-wide association studies (GWAS)
have clearly identified major histocompatibility com-
plex (MHC) region on chromosome 6p21, as the most
important effect size, with the majority of the single-
nucleotide polymorphisms (SNPs) that reached statis-
tical significance falling within this region [1, 2]. The
largest effect single-nucleotide polymorphism is the
well-established human leukocyte antigen (HLA) class
II region (HLA-DRB1*1501 in particular). Despite the
significant contribution of the MHC region to MS risk
and the large-scale GWAS study, there remains a large
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proportion of unexplained heritability in terms of MS
risk [1, 3].
The main environmental exposures presumed to
modify MS risk are smoking, sunlight exposure and
Epstein-Barr virus (EBV) (reviewed in [4]). Epigenetics
can influence the genome without changes to the DNA
sequence. Environmental exposures such as smoking
and sunlight exposure have been shown to be mediated
by epigenetic mechanisms, providing a plausible link
between environmental factors and disease [5, 6]. One
such epigenetic mechanism is DNA methylation, which
is the addition of a methyl group to CpG dinucleotides.
We, and others, have used genome-wide DNA methyla-
tion technologies to assess differentially methylated
regions (DMRs) of CD4+ and CD8+ T cells in relapsing-
remitting multiple sclerosis (RRMS) patients compared
to healthy controls [7–10]. These studies have found
inconsistent and/or conflicting results [7, 8, 10]. Both
groups found significant differences between CD4+ and
CD8+ T cells [7, 8, 10]; however, our studies found a
striking methylation signal located on chromosome
6p21 with a peak signal at HLA-DRB1, present in
relapsing-remitting patients compared to healthy con-
trols [7]. We found this signal to be specific to CD4+ T
cells, but Bos and colleagues did not see this in either
CD4+ or CD8+ T cells [8, 10].
The differences between the studies could be
explained in several ways. In our previous study, the
majority of patients were on some type of immunomod-
ulatory treatment as opposed to the Bos et al. study,
who used treatment naïve patients. Also, there were dif-
ferences in analysis methods in regard to filtering of
probes contained within the SNP heavy region in which
the methylation signal is contained in. In an effort to de-
termine if we could replicate our initial results under a
more tightly controlled study design, we performed a
genome-wide DNA methylation study of CD4+ T cells in
a new cohort of RRMS patients and healthy controls.
This cohort has a more accurately age- and gender-
matched control cohort and is comprised entirely of
treatment-naïve patients or patients who have been free
from immunomodulatory therapy for at least 3 months.
Identifying epigenetic loci associated with MS, independ-
ent of treatment or SNP effects, could reveal potentially
modifiable targets for environmental exposures or new
drug design as well as identify potential markers for
blood-based biomarkers of MS risk and treatment
response.
Methods
Subject recruitment
Whole blood was initially collected from 28 female
RRMS patients and 28 age-matched female healthy
donors (Table 1). We chose to focus only on females to
reduce potential sex effects and because female patients
are more at risk of RRMS compared to males. All
patients were diagnosed with MS according to the
McDonald criteria [11] and were treatment naïve (19
patients) or had not taken immunomodulatory or ster-
oid treatment for a minimum of 3 months (9 patients).
The purpose of this design feature was to control for
treatment effects as much as possible. Healthy control
samples were collected from volunteers off the Hunter
Medical Institute Research Register.
Blood sample processing and DNA methylation arrays
Peripheral blood mononucleocytes (PBMCs) were
isolated from whole blood by density gradient using
Lymphoprep (Stemcell Technologies, Canada) following
standard laboratory procedures. Total CD4+ T cells were
extracted from the PBMC population using EasySep
negative magnetic separation according to the manufac-
turers’ instructions (Stemcell Technologies, Canada).
After isolation, cell purity was assessed by flow cytome-
try. Cells were stained with a FITC-conjugated CD4
antibody (60016F1 StemCell Technologies, Canada) and
collected on a BD FACSCanto II flow cytometer, then
analysed using FACSDiva software (BD Biosciences). All
samples met the minimum purity cutoff of 90%. DNA
was extracted with the Qiagen microDNA extraction kit
(QIAGEN, USA) and biosulphite converted using the
MethylEasy Xceed kit according to the manufacturers’
instructions. Converted DNA was then applied to the
Illumina Infinium Human450K Beadchip methylation ar-
rays (service provided by Diamantina).
Data analysis
An in-house data analysis pipeline that used a combin-
ation of R/Bioconductor and custom scripts was
designed. Illumina 450k raw intensity data (idat files)
were parsed into the Bioconductor MINFI package [12].
Methylation data was background-corrected and
quantile-normalised according to MINFI routines. Data
was cleaned by removing (failed) CpG probes for which
the intensity of both the methylated and unmethylated
probes was <1000 units across all samples. A threshold
of 1000 units was selected based on the profile of the
available negative control probes. Y chromosome probes
Table 1 Clinical characteristics of the cohort
HC RRMS
Total 22 28
Age in years (mean ± SD) 38.2 ± 11.1 38.6 ± 12.7
EDSS (mean ± SD) n/a 2.1 ± 1.5
Disease duration in years (mean ± SD) n/a 7.6 ± 11.4
HC health control, RRMS relapsing-remitting multiple sclerosis, EDSS Expanded
Disability Status Scale
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were filtered out. All probe sequences were mapped to
the human genome (buildHg19) using BOWTIE [13] to
identify potential hybridisation anomalies. In total,
33,457 CpG probes were identified to align to the hu-
man genome multiple times and were filtered out of
subsequent analysis. We chose to retain probes contain-
ing SNPs and filter these out post hoc where
appropriate.
Measures of methylation level (β values) were
produced for each CpG probe and ranged from 0
[completely unmethylated] to 1 [completely methyl-
ated]. To identify differentially methylated positions
(DMPs) associated with MS subtypes in this cohort, the
DMPFinder function was implemented. This calculates
an F statistic for each CpG by comparing means be-
tween the case and control group. Subtracting control
mean from case mean produces a Δbeta score—a meas-
ure of differential methylation ranging from −1 to 1.
The Δbeta score can be broadly interpreted as percent-
age up or down methylation in cases compared to
controls (or effect size).
Given the relatively modest sample size, this study was
underpowered to detect significant DMPs at the
methylome-wide level and thus we used a series of pri-
oritisation steps to identify the most robust loci. Specif-
ically, a DMP was defined as containing CpGs (i) that
yielded a P < 0.05, i.e. nominally associated with MS,
and (ii) that yielded a Δbeta of ±0.1, i.e. a relatively large
differential methylation. Subsequently, a differentially
methylated region (DMR) was defined as a DMP (iii)
that had ≥2 adjacent CpGs within 1000-bp physical dis-
tance and (iv) whereby adjacent CpGs yielded a Δbeta in
the same direction, i.e. all three CpGs in the DMR were
consistently hypo- or hyper-methylated.
Gene set (or pathways) analysis was using the over-
representation analysis (ORA) routing of the WebGestalt
server (www.webgestalt.org/). Specifically, we entered
our gene list into the gene ontology—biological pro-
cesses database query—and used the default ORA pa-
rameters to explore whether our gene lists tended to
favour a particular pathway(s) at a false discovery rate
(FDR) of 5%.
Results
Identification of DMPs and DMRs associated with MS
We analysed CpG methylation data specifically for CD4+
T cells obtained from 28 female RRMS patients—all
treatment naïve—and 22 healthy age- and sex-matched
control subjects. NB: Six control subjects were dropped
due to poor quality methylation data. Clinical character-
istics of the patient group are shown in Table 1.
Following the QC steps, methylation data for 445,787
CpGs were analysed using DMPFinder to identify DMPs
associated with MS. A CpG prioritisation process was
used to select the most robustly associated DMPs. First,
all CpGs yielding a P < 0.05 were selected as being
nominally associated with MS. Secondly, of the result-
ant list, only CpGs yielding a Δbeta of ±0.1 were se-
lected. These steps resulted in 275 DMPs localising to
139 different genes and 136 unannotated genomic lo-
cations (see Additional file 1). Of the 275 DMPs, 134
(49%) were hypermethylated and 141 (51%) were
hypomethylated. The top hit was for cg10568066 in
the ring finger protein 39 (RNF39) gene whereby the
CpG was hypermethylated in the case group com-
pared to controls (Δbeta = 0.19, P = 2.1 × 10−4). A
gene ontology (pathways) analysis of the 134-gene set
revealed that the biological process involving
“regulation of GTPase activity” was over-represented
by the gene list—GO:0043087, FDR = 0.015 (Add-
itional file 2). GTPases are involved in signal trans-
duction and cell differentiation and have been the
target of many studies of MS.
Of the 275 DMPs, 14% are located within the MHC
region. Importantly, nine of these were identified in our
previous study and five are located in the main DMR we
previously reported to be associated with MS in CD4+ T
cells, i.e. HLA-DRB1 [7]. In addition to the previously
identified sites, we also identified three new CpGs within
the HLA-DRB1 DMR. All except one are located within
the same 400-bp region. We also observed hypermethy-
lated DMPs at HLA-DRB5 and HLA-DQB1 consistent
with our previous study (Additional file 1) [7]. At the
HLA-DRB5 region, we identified one previously identi-
fied probe plus an additional two sites. We did not see
any change in methylation at the CpG sites in HLA-
DRB6 previously identified, but did find two new
hypermethylated sites (Additional file 1).
To identify DMRs, we focused only on those DMPs (i)
that had ≥2 adjacent CpGs located within 1000-bp phys-
ical distance and (ii) whereby adjacent CpGs yielded a
Δmeth in a consistent direction, i.e. all CpGs in the
DMR were either hypo- or hyper-methylated. Table 2
shows the 33 DMPs representing six DMRs identified in
this study. The largest DMRs were located within the
MHC region on Chr 6. In addition to the DMR at HLA-
DRB1, there was another large DMR in MHC region at
RNF39. For this DMR, we observed 11 CpGs that were
hypermethylated in the MS case group compared to the
control (average Δbeta = −0.13). These CpGs were tightly
clustered within a 346-bp region of the gene body. This
region spans the boundary between intron 3 and exon 4
and spreads into exon 4 of RNF39.
To investigate whether or not SNP genotype might be
influencing methylation signal at the RNF39 DMR, we
first examined tracks on UCSC Genome Browser and
determined that there were no common SNPs in the im-
mediate vicinity of the CpGs in the DMR. Furthermore,
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we examined the methylation distribution for the largest
effect DMP (i.e. cg10568066), which showed a relatively
even spread of beta values within the MS and control
groups indicating that SNP genotype is not confounding
the signal (see Additional file 3).
Also within the MHC region, we identified a smaller
DMR of three CpGs within a 45-bp span at the tran-
scription start site (TSS) of the HLA complex group 4B-
non-protein coding (HCG4P6) (Table 1). Non-MHC
DMRs were also identified at PM20D1 on Chr 1 and
ERICH1 on Chr 8. Interestingly, none of the annotated
MS genes from the 110 non-HLA loci identified in the
GWAS by the IMSGC [1] were represented in our ex-
tended list of 134 genes that showed CpG methylation
changes as determined in this study. This may suggest
that the underlying genetic and epigenetic architecture
of MS is quite different outside of the MHC region.
Discussion
In this study, we report the results of an epigenome-
wide association study of methylation levels in CD4+ T
cells of treatment-naïve female RRMS patients compared
Table 2 Thirty-three DMPs representing six DMRs associated with MS
CpG ID Chr Pos (bp) DMR Gene Region F stat P value Control Case Δbeta
cg17178900 1 205,818,956 1 PM20D1 Body 6.54 0.014 0.470 0.646 0.176
cg26354017 1 205,819,088 1 PM20D1 1stExon 6.50 0.014 0.411 0.599 0.188
cg14159672 1 205,819,179 1 PM20D1 1stExon 6.09 0.017 0.444 0.616 0.173
cg14893161 1 205,819,251 1 PM20D1 5′UTR 7.42 0.009 0.328 0.498 0.169
cg11965913 1 205,819,406 1 PM20D1 TSS200 5.38 0.025 0.303 0.467 0.164
cg24503407 1 205,819,492 1 PM20D1 TSS1500 6.38 0.015 0.404 0.560 0.157
cg25644740 6 29,894,152 2 HCG4P6 TSS1500 5.93 0.019 0.448 0.612 0.164
cg04520169 6 29,894,195 2 HCG4P6 TSS1500 7.27 0.010 0.377 0.524 0.148
cg23237314 6 29,894,197 2 HCG4P6 TSS1500 6.97 0.011 0.374 0.492 0.117
cg08491487 6 30,039,130 3 RNF39 Body 10.02 0.003 0.078 0.181 0.103
cg00947782 6 30,039,142 3 RNF39 Body 12.34 0.001 0.102 0.210 0.108
cg03343571 6 30,039,175 3 RNF39 Body 13.64 0.001 0.212 0.334 0.122
cg13185413 6 30,039,202 3 RNF39 Body 11.78 0.001 0.206 0.326 0.119
cg09279736 6 30,039,403 3 RNF39 Body 14.19 0.000 0.287 0.404 0.117
cg07382347 6 30,039,408 3 RNF39 Body 13.22 0.001 0.153 0.295 0.142
cg13401893 6 30,039,432 3 RNF39 Body 19.38 0.000 0.350 0.508 0.158
cg12633154 6 30,039,435 3 RNF39 Body 18.69 0.000 0.310 0.477 0.167
cg10568066 6 30,039,442 3 RNF39 Body 22.29 0.000 0.372 0.560 0.188
cg16078649 6 30,039,466 3 RNF39 Body 13.37 0.001 0.346 0.451 0.105
cg10930308 6 30,039,476 3 RNF39 Body 12.69 0.001 0.193 0.317 0.125
cg01341801 6 32,489,203 4 DRB5 Body 4.419 0.041 0.249 0.455 0.205
cg26981746 6 32,490,012 4 DRB5 Body 4.645 0.036 0.501 0.633 0.132
cg12015991 6 32,490,043 4 DRB5 Body 5.591 0.022 0.649 0.778 0.128
cg08578320 6 32,552,039 5 DRB1 Body 6.558 0.014 0.754 0.588 −0.166
cg09139047 6 32,552,042 5 DRB1 Body 5.129 0.028 0.754 0.576 −0.179
cg15602423 6 32,552,095 5 DRB1 Body 8.966 0.004 0.659 0.387 −0.272
cg15982117 6 32,552,106 5 DRB1 Body 5.811 0.020 0.684 0.492 −0.192
cg14645244 6 32,552,205 5 DRB1 Body 6.068 0.017 0.521 0.318 −0.203
cg09949906 6 32,552,350 5 DRB1 Body 5.076 0.029 0.699 0.507 −0.192
cg10632894 6 32,552,453 5 DRB1 Body 4.536 0.038 0.825 0.681 −0.144
cg01053087 8 637,909 6 ERICH1 Body 10.55 0.002 0.330 0.164 −0.166
cg05875700 8 638,208 6 ERICH1 Body 8.864 0.005 0.319 0.120 −0.199
cg12641240 8 638,330 6 ERICH1 Body 6.055 0.018 0.194 0.069 −0.125
DMP differentially methylated position, DMR differentially methylated region
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to age-matched healthy controls. In our previous study,
which included patients on treatment, we found a DMR
consisting of eight hypomethylated CpGs in HLA-DRB1
[7]. In the current study, we were able to confirm five of
these CpG sites, plus an additional three CpG sites clus-
tered within the same 358-bp region. Although there is a
lower effect size in the current study, the differential
methylation occurs in the same direction (primarily
hypomethylation). These results confirm the signal we
saw in our original study and suggest this is not due to
treatment effects. Another study by Bos et al. [8] did not
find any changes at the HLA-DRB1 locus. However, this
study filtered all probes that had a SNP in the probe
sequence on the assumption that SNPs may affect the
signal at these probes. This removed all probes at HLA-
DRB1 that we find to have altered methylation status in
this study. We did not remove these probes using our
filters, and since the methylation signal is absent in CD8
+ T cells derived from the same cohort, it is unlikely that
SNP genotype underpins this DMR [10].
Interestingly, this study also identified an independent
DMR in the MHC region in CD4+ T cells as being asso-
ciated with MS, specifically, a large hypermethylated
DMR in RNF39. The biological relevance of this locus
can only be speculated at this stage; however, it resides
within the gene body and spans an intron/exon bound-
ary, so it is plausible that hypermethylation is involved
in aberrant expression of alternately spliced transcripts
or a regulatory element for nearby genes. RNF39 is a
poorly characterised gene. In rats, RNF39 encodes a
protein that plays a role in the early phase of synaptic
plasticity [14].
Interestingly, one of the sites identified in the RRMS
cohort (cg10568066) was also identified in a recent study
that investigated the role of CpG methylation sites and
ageing [15]. RNF39 is also associated with other auto-
immune conditions, such as Becet’s disease, a chronic
relapsing inflammatory disease [16]. This study found a
SNP near RNF39 associated with the disease, although
the functional consequences of this are not yet known.
In addition, hypermethylation of 11 CpGs sites within
RNF39 was seen in naïve CD4+ T cells of patients with
systemic lupus erythematosus (SLE) who had a history
of discoid rash [17]. Furthermore, eight of these sites are
the same sites as those we have identified in this study
(cg10568066, cg12633154, cg13401893, cg10930308,
cg03343571, cg13185413, cg09279736, cg00947782) and
have similar Δbeta values to our RRMS cohort
(meanRRMS = 0.13; meanSLE = 0.16) [17].
Although this study controlled for sex, age and treat-
ment effects (as much as possible), there is a possibility
that methylation at RNF39 may be under the influence
of other factors that were not measured in this study,
e.g., exposure to Epstein-Barr virus (EBV) and smoking.
A search of the literature at the time of writing did not
reveal any studies reporting an association of RNF39
methylation with known environmental risk factors of
MS. However, one study did reveal an association with
hepatitis B vaccination response [18] which suggests
that future, larger scale studies of RNF39 and MS
should attempt to include factors such as EBV as covar-
iates in the analysis.
Conclusions
In conclusion, the findings from this study confirm our
previous results at the MS risk locus HLA-DRB1 and
also suggest hypermethylation in an independent MHC
locus, RNF39, is also associated with MS. Taken
together, our results highlight the importance of epigen-
etic factors at the MHC locus in MS independent of
treatment, age and sex. Prospective studies are now
required to discern whether methylation at MHC is
involved in influencing risk of disease onset or whether
the disease itself has altered the methylation profile.
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